Phase I/II Study of TLR7 Agonist Imiquimod and Radiotherapy in Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases

Trial Profile

Phase I/II Study of TLR7 Agonist Imiquimod and Radiotherapy in Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Imiquimod (Primary)
  • Indications Advanced breast cancer; Cancer metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Feb 2017 Planned End Date changed from 1 Sep 2018 to 1 Feb 2019.
    • 16 Feb 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Feb 2018.
    • 16 Feb 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top